04.16.21

New Long-Term Data for Uplizna in People Living With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Source: Horizon Therapeutics

04.02.21

Horizon Therapeutics to Resupply Market With Tepezza for the Treatment of Thyroid Eye Disease (TED) Beginning in April

Source: Horizon Therapeutics

03.24.21

Uplinza Approved in Japan for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder (NMOSD)

Source: Horizon Therapeutics

02.24.21

New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Beyond Acute Disease into Chronic Phase

Source: Horizon Therapeutics

02.01.21

Horizon Therapeutics to Acquire Viela Bio to Grow Rare Disease Medicine Portfolio

Source: Horizon Therapeutics

11.16.20

Horizon: New Data Build on Growing Evidence Supporting Tepezza Efficacy in Thyroid Eye Disease (TED)

Source: Horizon Therapeutics

11.11.20

New Data for Thyroid Eye Disease Treatment Tepezza to Be Presented at AAO Virtual

Source: Horizon Therapeutics

10.14.20

Tepezza Data From Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED)

Source: Horizon Therapeutics

07.31.20

New Topline Tepezza Data Underscore its Efficacy in Potential for Retreatment in People Living with Thyroid Eye Disease (TED)

Source: Horizon Therapeutics

07.01.20

New Initiative Encourages the Graves’ Disease Community to FOCUS on Eye Health

Source: Horizon Therapeutics

View more stories